Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real-World Study

Background: Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease (PD), highly impacting on quality-of-life and health-related costs. Objectives: Aim of our real-world study was to evaluate the impact of Foslevodopa/Foscarbidopa (LDp/CDp) subcutaneous infusion (CSCI) on nocturia in a group of advanced PD patients. Methods: Seventy-eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale (IPSS) and Nocturia Quality of Life (NQoL) questionnaire were administrated before starting LDp/CDp CSCI and after three months of infusion. Results: In this cohort, LDp/CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS-UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post-pre changes of IPSS and LEED showed a negative correlation. Conclusions: This study supports the utility of the overnight dopaminergic stimulation with LDp/CDp CSCI in controlling overactive bladder.